文献速递肾移植

移植前抗HLA抗体对移植物存活影响的配对肾脏分析

A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.
PubMed 文献 · Nephrol Dial Transplant · 2019-01-01

该研究通过荷兰多中心1995-2005年死亡供肾移植的配对肾脏分析,比较供者特异性抗HLA抗体(DSA)与非供者特异性抗HLA抗体(nDSA)的临床相关性。结果显示移植前DSA阳性者10年死亡删失移植物存活率显著低于无抗体者(55% vs 82%,P=0.0001),而nDSA总体与移植物存活无显著关联(74% vs 77%,P=0.79),仅I类和II类nDSA均阳性者呈较低存活趋势(58%,P=0.06)。

要点

  • 移植前DSA是死亡供肾移植移植物丢失的风险标志。
  • nDSA总体与10年移植物存活无显著关联。
  • I类和II类nDSA均阳性者长期移植物丢失风险可能增加。

核心结论

  • 配对肾脏分析证实移植前DSA是移植物丢失的风险标志,而nDSA总体不降低移植物存活。
  • 亚组分析提示仅I类和II类nDSA均阳性的广泛致敏患者中nDSA可能为长期移植物丢失风险标志。

研究设计与样本

  • 荷兰多中心研究的事后配对肾脏移植分析,纳入1995-2005年有移植前血清样本的死亡供肾移植。
  • 从3237例死亡供肾移植中识别115对DSA阳性与无抗HLA抗体配对、192对nDSA阳性与无抗体配对、42对DSA与nDSA配对。
  • 抗HLA抗体采用Luminex单抗原珠法检测。

主要发现

  • DSA阳性者10年死亡删失移植物存活率显著低于无抗HLA抗体者(55% vs 82%,P=0.0001)。
  • nDSA针对I类或II类者与无抗体者移植物存活无显著差异(74% vs 77%,P=0.79)。
  • I类和II类nDSA均阳性者移植物存活呈较低趋势(58%,P=0.06)。
  • 42对DSA与nDSA配对中,10年移植物存活率分别为49%与68%(P=0.11)。

临床怎么用

  • 移植前应检测DSA以评估移植物丢失风险。
  • nDSA阳性总体不预示移植物存活降低,但I类和II类nDSA均阳性者需关注长期移植物丢失风险。

局限性

  • 为事后配对分析,部分亚组样本量较小(如42对),统计效能有限。
  • 研究纳入1995-2005年移植病例,抗体检测与免疫抑制方案可能已随时间变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pre-transplant donor-specific anti-human leucocyte antigen (HLA) antibodies (DSAs) are associated with impaired kidney graft survival while the clinical relevance of non-donor-specific anti-HLA antibodies (nDSAs) is more controversial. The aim of the present paired kidney graft study was to compare the clinical relevance of DSAs and nDSAs. METHODS: To eliminate donor and era-dependent factors, a post hoc paired kidney graft analysis was performed as part of a Dutch multicentre study evaluating all transplantations between 1995 and 2005 with available pre-transplant serum samples. Anti-HLA antibodies were detected with a Luminex single-antigen bead assay. RESULTS: Among 3237 deceased donor transplantations, we identified 115 recipient pairs receiving a kidney from the same donor with one recipient being DSA positive and the other without anti-HLA antibodies. Patients with pre-transplant DSAs had a significantly lower 10-year death-censored graft survival (55% versus 82%, P=0.0001). We identified 192 pairs with one recipient as nDSA positive (against Class I and/or II) and the other without anti-HLA antibodies. For the patients with nDSAs against either Class I or II, graft survival did not significantly differ compared with patients without anti-HLA antibodies (74% versus 77%, P = 0.79). Only in patients with both nDSAs Class I and II was there a trend towards a lower graft survival (58%, P = 0.06). Lastly, in a small group of 42 recipient pairs, 10-year graft survival in recipients with DSAs was 49% compared with 68% in recipients with nDSAs (P=0.11). CONCLUSION: This paired kidney analysis confirms that the presence of pre-transplant DSAs in deceased donor transplantations is a risk marker for graft loss, whereas nDSAs in general are not associated with a lower graft survival. Subgroup analysis indicated that only in broadly sensitized patients with nDSAs against Class I and II, nDSAs may be a risk marker for graft loss in the long term.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Michielsen LA, Wisse BW, Kamburova EG, et al. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. Nephrol Dial Transplant. 2019. PMID: 30365008. doi:10.1093/ndt/gfy316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。